Genzyme Corp. will pay Voyager Therapeutics up to $945 million for rights to a variety of treatments for brain diseases including Parkinson’s, Friedreich’s Ataxia and Huntington’s disease.

The price tag includes about $100 million up front, made up of $65 million in cash, and roughly $30 million in equity, plus additional cash depending on various development and sales milestones, should the products ultimately reach the market. As part of the deal, Genzyme gains access to Voyager’s experimental gene therapies for Parkinson’s and Friedreich’s, an inherited disease that causes progressive damage to the nervous system.

Voyager, a startup, received a $45 million Series A round by Third Rock Ventures in 2014. The Cambridge, Massachusetts-based company focuses on developing medication for diseases that affect the central nervous system.

Genzyme, also headquartered in Cambridge, develops medications for patients who have rare and debilitating diseases. The buyer is part of pharmaceutical group Sanofi (NYSE: SNY).

Other recent pharmaceutical deals have come from Mylan Inc. (Nasdaq: MYL), which agreed to buy part of Famy Care Ltd. for $750 million in February, and Valeant, which plans to buy bankrupt Dendreon

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.